Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients

被引:14
|
作者
Pease, Daniel F. [1 ]
Ross, Julie A. [2 ]
Poynter, Jenny N. [2 ]
Nguyen, Phuong L. [3 ]
Hirsch, Betsy [4 ]
Cioc, Adina [5 ]
Roesler, Michelle A. [2 ,6 ]
Warlick, Erica D. [7 ]
机构
[1] Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA
[2] Univ Minnesota, Dept Pediat, Minneapolis, MN 55454 USA
[3] Mayo Clin, Div Hematopathol, Rochester, MN 55905 USA
[4] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[5] VA Med Ctr, Hematopathol, Minneapolis, MN 55417 USA
[6] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN 55455 USA
[7] Univ Minnesota, Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA
关键词
Myelodysplastic syndromes; Hematologic malignancies; Drug therapy; Bone marrow transplantation; STEM-CELL TRANSPLANTATION; PROGNOSTIC SCORING SYSTEM; RETROSPECTIVE MULTICENTER ANALYSIS; CONVENTIONAL CARE REGIMENS; IDENTICAL SIBLING DONORS; ACUTE MYELOID-LEUKEMIA; DECISION-ANALYSIS; OLDER PATIENTS; PHASE-III; THERAPY;
D O I
10.1016/j.canep.2015.01.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The heterogeneous nature of myelodysplastic syndromes (MDS) complicates therapeutic decision making, particularly for newly diagnosed disease. Factors impacting the treatment plan in this early period of disease course are poorly defined. This study determines whether therapeutic choices for newly diagnosed MDS are associated with location of treatment (community or academic), prognostic risk category, and patient age. Methods: The adults in Minnesota with myelodysplastic syndromes (AIMMS) database was utilized in this statewide, prospective population-based study conducted by the University of Minnesota (UMN), Mayo Clinic, and Minnesota Department of Health. Adult (age 20+ years) cases of MDS newly diagnosed starting in April 2010 were invited to participate. This analysis includes patients enrolled during the first study year with 1-year follow-up data. Treatment choices (supportive, active, and transplant) were stratified by the international prognostic scoring system (IPSS) and the revised-IPSS (IPSS-R), then separated into groups by location of care and age (<65 or 65+ years). Academic-based care was any contact with the UMN and Mayo Clinic; community-based care was all other clinical sites. Results: Stratification by IPSS and IPSS-R showed supportive care decreased and active care increased with advancing risk categories (p < 0.0001). Comparing treatment setting, community-based care had 77% supportive and 23% active treatment; academic-based care was 36% supportive, 41% active, and 23% transplant (p < 0.0001). By age groups, patients < 65 years with intermediate, high, or very high risk disease by IPSS-R received 97% active care/transplant, compared to only 52% of patients age 65+. Conclusions: Younger patients and those treated at academic centers had a more aggressive treatment approach. Whether these treatment differences convey improved disease control and mortality, and therefore should be extended more frequently to older and community-based patients, is the subject of ongoing prospective study. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:222 / 228
页数:7
相关论文
共 50 条
  • [31] CHROMOSOMAL RESULTS IN 50 PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    LESSARD, M
    BRIZARD, A
    GUILHOT, F
    TANZER, J
    BLUT, 1988, 56 (06): : C9 - C9
  • [32] Impact of Transfusion Dependency on Health-Related Quality of Life Outcomes in Newly Diagnosed Patients with Myelodysplastic Syndromes (MDS). Analysis on 669 Patients By Disease Risk
    Efficace, Fabio
    Niscola, Pasquale
    Gaidano, Gianluca
    Ricco, Alessandra
    Caocci, Giovanni
    Breccia, Massimo
    Palumbo, Giuseppe A.
    Voso, Maria Teresa
    Vallisa, Daniele
    Allione, Bernardino
    Canicatti, Manuela
    Okumura, Iris
    Cottone, Francesco
    Invernizzi, Rosangela
    Bergamaschi, Micaela
    Borin, Lorenza Maria
    Di Tucci, Anna Angela
    Zhang, Huiyong
    Stauder, Reinhard
    Platzbecker, Uwe
    Luppi, Mario
    Petranovic, Duska
    Caers, Jo
    Cascavilla, Nicola
    Vignetti, Marco
    Mandelli, Franco
    BLOOD, 2017, 130
  • [33] Differences In Perceptions Of Disease and Treatment Effectiveness and Adherence Between Physicians and Patients With Myelodysplastic Syndromes (MDS)
    Steensma, David P.
    Stone, Richard M.
    Huber, John
    Dennison, Betsy
    Sekeres, Mikkael A.
    BLOOD, 2013, 122 (21)
  • [34] Iron overload impact on peripheral blood cells, lymphocytes and karyotypes in newly diagnosed myelodysplastic syndromes (MDS) patients: a single-center retrospective analysis
    Duan, Lixiang
    Yu, Wenjun
    Jiao, Xiaolin
    Sun, Ying
    Ma, Yao Fang
    Li, Le
    Nie, Zeqiang
    Zhao, Dan
    ALL LIFE, 2024, 17 (01)
  • [35] Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis
    Zemanova, Zuzana
    Michalova, Kyra
    Buryova, Halka
    Brezinova, Jana
    Kostylkova, Karla
    Bystricka, Dagmar
    Novakova, Milena
    Sarova, Iveta
    Izakova, Silvia
    Lizcova, Libuse
    Ransdorfova, Sarka
    Krejcik, Zdenek
    Merkerova, Michaela Dostalova
    Dohnalova, Alena
    Siskova, Magda
    Jonasova, Anna
    Neuwirtova, Radana
    Cermak, Jaroslav
    LEUKEMIA RESEARCH, 2014, 38 (05) : 537 - 544
  • [36] Azacitidine: Duration of treatment used in routine clinical practice in patients with myelodysplastic syndromes (MDS) in England
    Legg, A.
    Killick, S.
    Farrell, J.
    Le Reun, C.
    Howells, R.
    Vyas, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 79 - 79
  • [37] Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes
    Hutzschenreuter, Franz
    Monsef, Ina
    Kreuzer, Karl-Anton
    Engert, Andreas
    Skoetz, Nicole
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02):
  • [38] Anisocytosis Is Associated With Decreased Survival In Patients With Newly Diagnosed Myelodysplastic Syndromes: A Single Center Experience
    Sridharan, Ashwin
    Jain, Rishi
    Bachhuber, Marcus
    Lam, Anthony P.
    Yu, Yiting
    Friedman, Ellen W.
    Verma, Amit
    BLOOD, 2013, 122 (21)
  • [39] CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES (MDS) IN DAILY PRACTICE: A POPULATION-BASED STUDY AMONG 8912 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 2001 TO 2014
    Dinmohamed, A.
    Visser, O.
    Jongen-Lavrencic, M.
    van de Loosdrecht, A.
    HAEMATOLOGICA, 2016, 101 : 244 - 245
  • [40] Increased Pronormoblasts are Associated with Adverse Prognosis in Newly Diagnosed Myelodysplastic Syndromes
    Ta, Robert
    Loneman, Derek
    Hasserjian, Robert
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1247 - S1248